Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NNOX 
Nano X Imaging Ltd (NNOX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NNOX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.76% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 251.92M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 4 | Beta 1.94 | 52 Weeks Range 3.75 - 11.00 | Updated Date 08/29/2025 |
52 Weeks Range 3.75 - 11.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.19 | Actual -0.17 |
Profitability
Profit Margin - | Operating Margin (TTM) -475.59% |
Management Effectiveness
Return on Assets (TTM) -18.97% | Return on Equity (TTM) -32.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 207927102 | Price to Sales(TTM) 21.19 |
Enterprise Value 207927102 | Price to Sales(TTM) 21.19 | ||
Enterprise Value to Revenue 17.49 | Enterprise Value to EBITDA -7.41 | Shares Outstanding 63939600 | Shares Floating 61163362 |
Shares Outstanding 63939600 | Shares Floating 61163362 | ||
Percent Insiders 0.23 | Percent Institutions 20.83 |
Upturn AI SWOT
Nano X Imaging Ltd
Company Overview
History and Background
Nano X Imaging Ltd. (Nanox) was founded in 2012. It aims to revolutionize medical imaging by developing a more affordable and accessible X-ray technology based on its proprietary digital microelectromechanical systems (MEMS) technology.
Core Business Areas
- Nanox System: Developing and commercializing a digital X-ray source based on MEMS technology for medical imaging applications.
- Cloud Services: Offering cloud-based medical imaging services, including image storage, analysis, and reporting.
Leadership and Structure
Erez Meltzer serves as the Chief Executive Officer. The company has a board of directors overseeing the overall strategy and governance.
Top Products and Market Share
Key Offerings
- Nanox.ARC: A multi-source 3D digital tomosynthesis system designed to improve accessibility and reduce the cost of medical imaging. Market share data is difficult to obtain as the product is still in early commercialization. Competitors include Siemens Healthineers (SIEGY), GE Healthcare (GE), and Philips (PHG).
- Nanox.CLOUD: A cloud-based infrastructure intended to facilitate the delivery of medical imaging services. Revenue data is not currently readily available. Competitors are various cloud platforms like AWS, Azure, and Google Cloud, as well as specialized medical imaging cloud providers.
Market Dynamics
Industry Overview
The medical imaging market is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The industry is characterized by high barriers to entry due to regulatory requirements and the need for significant capital investment.
Positioning
Nanox aims to disrupt the traditional medical imaging market by offering a lower-cost and more accessible alternative to conventional X-ray technology. Its competitive advantage lies in its MEMS-based digital X-ray source.
Total Addressable Market (TAM)
The global medical imaging market is projected to reach hundreds of billions of USD. Nanox is positioned to capture a portion of this TAM by offering a cost-effective and accessible solution.
Upturn SWOT Analysis
Strengths
- Innovative MEMS-based technology
- Potential for cost reduction in medical imaging
- Focus on accessibility and global health
- Cloud-based service platform
Weaknesses
- Commercialization is still in early stages
- Regulatory hurdles and approval processes
- Limited track record of sales and revenue
- Reliance on third-party manufacturing
Opportunities
- Expanding into underserved markets
- Partnerships with healthcare providers and distributors
- Developing new applications for its technology
- Increasing demand for remote medical imaging
Threats
- Competition from established medical imaging companies
- Technological advancements by competitors
- Regulatory changes and compliance requirements
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens Healthineers (SIEGY)
- Philips (PHG)
- Canon Medical Systems (Canon)
Competitive Landscape
Nanox is a relatively small player compared to established competitors. Its advantage is lower cost, but its disadvantage is the lack of an established customer base and regulatory history.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the product being in early stages of commercialization.
Future Projections: Analyst projections vary widely depending on the successful commercialization and regulatory approval of Nanox's products.
Recent Initiatives: Recent initiatives include obtaining regulatory approvals, establishing manufacturing partnerships, and expanding distribution networks.
Summary
Nano X Imaging Ltd. is a developing company with a novel approach to medical imaging. Its success depends on obtaining regulatory approvals and successfully commercializing its products. The company's MEMS-based technology has the potential to disrupt the market, but it faces significant competition from established players and financial challenges. The company needs to demonstrate successful implementation and adoption of its product to gain market trust.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nano X Imaging Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-21 | CEO & Acting Chairman of the Board Mr. Erez I. Meltzer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 165 | Website https://www.nanox.vision |
Full time employees 165 | Website https://www.nanox.vision | ||
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide and obtain remote interpretations of imaging data; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. The company was founded in 2011 and is headquartered in Petah Tikva, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.